⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14814529 | 0.80 | ALDH1A1 (0.47) | — | |
| SCHEMBL18484306 | 0.79 | — | — | |
| SCHEMBL14814527 | 0.75 | — | — | |
| SCHEMBL25358451 | 0.73 | — | — | |
| SCHEMBL11214348 | 0.72 | TSHR (0.31) | — | |
| SCHEMBL21252626 | 0.71 | ALDH1A1 (0.30) | — | |
| SCHEMBL13728707 | 0.69 | HTT (0.30) | — | |
| SCHEMBL15870743 | 0.69 | ALDH1A1 (0.50) | — | |
| SCHEMBL757735 | 0.69 | — | — | |
| SCHEMBL29216435 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0988061-A4 | METHODS FOR DELIVERING BIOACTIVE AGENTS | IMARX PHARMACEUTICAL CORP (US) | 2002-05-02 | — | — | EP | claimed |
| US-6143276-A | ADMINISTERING TO THE PATIENT A COMPOSITION COMPRISING A BIOACTIVE AGENT AND A GASEOUS PRECURSOR CAPABLE OF UNDERGOING PHASE TRANSITION TO A GAS AT A REGION OF ELEVATED TEMPERATURE IN THE PATIENT | IMARX PHARMACEUTICAL CORP. (US) | 2000-11-07 | — | — | US | claimed |
| EP-0988061-A1 | METHODS FOR DELIVERING BIOACTIVE AGENTS | IMARX PHARMACEUTICAL CORP. (US) | 2000-03-29 | — | — | EP | claimed |
| WO-1998042384-A1 | METHODS FOR DELIVERING BIOACTIVE AGENTS | IMARX PHARMACEUTICAL CORP. (US) | 1998-10-01 | — | — | WO | claimed |
| EP-2766001-B1 | BUFFERED OXYGEN THERAPEUTIC | NUVOX PHARMA LLC (US) | 2024-05-15 | — | — | EP | disclosed |
| US-20170071193-A1 | FLUID FOR SUSPENDED ANIMATION | NUVOX PHARMA LLC (US) | 2017-03-16 | — | — | US | disclosed |
| US-8822549-B2 | Buffered oxygen therapeutic | NUVOX PHARMA LLC | 2014-09-02 | — | — | US | disclosed |
| EP-2766001-A1 | BUFFERED OXYGEN THERAPEUTIC | Nuvox Pharma, LLC (US) | 2014-08-20 | — | — | EP | disclosed |
| US-20130330706-A1 | Fluid for Suspended Animation | NUVOX PHARMA, L.L.C. | 2013-12-12 | — | — | US | disclosed |
| US-20130096204-A1 | Buffered Oxygen Therapeutic | NUVOX PHARMA LLC | 2013-04-18 | — | — | US | disclosed |
| WO-2013056246-A1 | BUFFERED OXYGEN THERAPEUTIC | NUVOX PHARMA L.L.C. (US) | 2013-04-18 | — | — | WO | disclosed |
| EP-1015039-B1 | OXYGEN DELIVERY AGENTS AND USES FOR THE SAME | IMARX PHARMACEUTICAL CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-0988061-A1 | METHODS FOR DELIVERING BIOACTIVE AGENTS | IMARX PHARMACEUTICAL CORP. (US) | 2000-03-29 | — | — | EP | disclosed |
| US-6028066-A | FOR DELIVERING HIGHER CONCENTRATIONS OF BIOACTIVE AGENTS TO IMPROVE EFFICACY OF THE BIOACTIVE AGENTS | IMARX PHARMACEUTICAL CORP. (US) | 2000-02-22 | — | — | US | disclosed |
| WO-1999030620-A1 | OPTOACOUSTIC CONTRAST AGENTS AND METHODS FOR THEIR USE | IMARX PHARMACEUTICAL CORP. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0901793-A1 | Thermal preactivation of gaseous precursor filled compositions | IMARX PHARMACEUTICAL CORP. (US) | 1999-03-17 | — | — | EP | disclosed |
| WO-1998057670-A1 | OXYGEN DELIVERY AGENTS AND USES FOR THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 1998-12-23 | — | — | WO | disclosed |
| WO-1998050041-A1 | NOVEL PRODRUGS COMPRISING FLUORINATED AMPHIPHILES | IMARX PHARMACEUTICAL CORP. (US) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998042383-A1 | CHARGED LIPIDS AND USES FOR THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 1998-10-01 | — | — | WO | disclosed |
| WO-1998042384-A1 | METHODS FOR DELIVERING BIOACTIVE AGENTS | IMARX PHARMACEUTICAL CORP. (US) | 1998-10-01 | — | — | WO | disclosed |